RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $75

Benzinga Newsdesk www.benzinga.com Negative 87.8%

Neg 87.8% Neu 0% Pos 0%

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and lowers the price target from $85 to $75.